Full Press Release Details
Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen
Receptor T-Cell Therapy in Scientific Reports
a Next Generation CAR, Allows for the Purification, Detection and
Efficient Elimination of CAR T-Cells
NEW YORK--(BUSINESS WIRE)--June 12, 2018--Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS),
a biopharmaceutical company focused on developing immunotherapies based
on gene edited CAR T-cells (UCART), today announced the publication of a
study in Scientific Reports, a Nature Publishing Group journal,
describing the development of the CubiCAR, an all-in-one Chimeric
Antigen Receptor (CAR) architecture with an embedded multi-functional
tag for purification, detection and elimination of CAR T-cells. This
added versatility has the potential to streamline the manufacturing of
CAR T-cells to allow their tracking and efficiently eliminate CAR
T-cells in clinical settings.
"The power and novelty of this technology lies in the integration of
these multiple functions in one unique CAR molecule. To identify an
optimal CAR architecture, we selected 15 different CAR constructs and
evaluated their ability to enable T-cell depletion and promote tumor
eradication," said Julien Valton, Ph.D., Innovation Team Leader of
Cellectis. "The development of this novel architecture was in
collaboration with our colleagues at Allogene."
"The CubiCAR architecture represents a major step forward in the
development of CAR-T therapies in the treatment of various cancers,"
added Philippe Duchateau, Ph.D., Chief Scientific Officer of Cellectis.
"Not only is the CubiCAR architecture an integrated, compact safeguard
allowing for the fast and efficient depletion of CAR T-cells, it is also
compatible with multiple scFvs that are designed against different
targets, which gives it the unique potential to make CAR T-cell
immunotherapies safer."
"The transformational impact of autologous CAR T therapy for the
treatment of hematologic cancers has been firmly established. We plan to
evaluate this CubiCAR approach and other novel CAR T engineering
developed in partnership with our colleagues at Cellectis across our
extensive CAR T pipeline," said Barbra Sasu, Ph.D., Chief Scientific
Officer of Allogene. "As we look to the future of allogeneic cell
therapy, we can apply the scientific understanding gained from earlier
therapies to the next wave of innovation to develop best-in-class
allogeneic cell therapy."
Julien Valton, Ph.D., Innovation Team Leader, Cellular Engineering &
Adoptive CAR T-Cell Immunotherapy
Dr. Julien Valton obtained his Ph.D. at the University Joseph Fourier in
Grenoble, France, where he was trained as an enzymologist. He then
joined the Yale School of Medicine to apply his knowledge to therapeutic
research by investigating the mechanism of inhibition of receptor
tyrosine kinases that are involved in the development of
gastrointestinal cancer. In 2009, he moved a step further into the field
of applied science by joining the Innovation Department of Cellectis,
where he actively participated in using and improving TALEN gene
editing technology for targeted gene therapy and genome engineering. He
is now using TALEN along with protein engineering techniques to develop
the next-generation CAR T-cells to treat different malignancies.
A Versatile Safeguard for Chimeric Antigen Receptor T-Cell
Julien Valton1, Valerie Guyot2, Bijan Boldajipour4,
Cesar Sommer3, Thomas Pertel3 Alexandre Juillerat1,
Aymeric Duclert2, Barbra Johnson Sasu3, Philippe
Duchateau2 and Laurent Poirot2
Inc., 430E, 29th Street, NYC, NY 10016, USA;
2 Cellectis S.A., 8 rue
de la Croix Jarry, 75013 Paris, France;
3 Allogene Therapeutics, 270
Littlefield Ave., South San Francisco, CA 94080, USA;
230 E Grand Ave, South San Francisco, CA 94080, USA.
Cellectis is a clinical-stage biopharmaceutical company focused on
developing a new generation of cancer immunotherapies based on
gene-edited T-cells (UCART). By capitalizing on its 18 years of
expertise in gene editing - built on its flagship TALEN technology and
pioneering electroporation system PulseAgile - Cellectis uses the power
of the immune system to target and eradicate cancer cells.
Using its life-science-focused, pioneering genome engineering
technologies, Cellectis' goal is to create innovative products in
multiple fields and with various target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on Euronext
Growth (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
Talking about gene editing? We do it. TALEN is a registered trademark
This press release contains "forward-looking" statements that are based
on our management's current expectations and assumptions and on
information currently available to management. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements.
Further information on the risk factors that may affect company business
and financial performance is included in Cellectis' Annual Report on
Form 20-F and the financial report (including the management report) for
the year ended December 31, 2017 and subsequent filings Cellectis makes
with the Securities Exchange Commission from time to time. Except as
required by law, we assume no obligation to update these forward-looking
statements publicly, or to update the reasons why actual results could
differ materially from those anticipated in the forward-looking
statements, even if new information becomes available in the future.
For further information, please contact:
Jennifer Moore, 917-580-1088
Caitlin Kasunich, 212-896-1241
Simon Harnest, 646-385-9008
Corporate Strategy and Finance